Trial Profile
A Three-Arm Study of ME-401 Monotherapy in Subjects With Relapsed/Refractory CLL, SLL, or FL, of ME-401 in Combination With Rituximab in Subjects With Relapsed/Refractory CLL/SLL or B-cell NHL, and of ME-401 in Combination With Zanubrutinib in Subjects With Relapsed/Refractory CLL/SLL or B-cell NHL
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 11 May 2023
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Zandelisib (Primary) ; Zanubrutinib (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Proof of concept
- Sponsors MEI Pharma
- 05 May 2023 Status changed from active, no longer recruiting to discontinued.
- 13 Dec 2022 Results (n=50) assessing the safety and efficacy of zandelisib in combination with zanubrutinib in patients with relapsed/refractory follicular lymphoma (n=31; enrolled between Feb 2020 and Oct 2021) or mantle cell lymphoma (n=19; enrolled between Jan 2021 and May 2022), presented at the 64th American Society of Hematology Annual Meeting and Exposition.
- 03 Nov 2022 According to a MEI Pharma media release, results from the study will be presented at the upcoming American Society of Hematology (ASH) 2022 Annual Meeting.